Now Open: CDK Study

Written By Erica Stupfel

Are you 65 or older with HR+/HER2- metastatic breast cancer? If you haven’t had prior treatment with a CDK4/6 inhibitor, consider the ASCO CDK Study. It aims to find the best  CDK4/6 dosing strategy. The goal is to help patients stay on treatment longer with fewer side effects.

Patients and their doctors choose a study drug: palbociclib or ribociclib. They also choose an endocrine therapy: an aromatase inhibitor or fulvestrant. Some patients will start at a lower dose and increase as tolerated. Others will begin at the FDA-approved dose.

The CDK Study is available at cancer centers and clinics across the United States. For more details, talk to your oncologist or visit www.cdkstudy.org.

Erica Stupfel

e*design Creative Services specializes in making professional design available to small companies and individuals. I understand the importance in brand identity and how a positive visual representation of your product or service can make the difference between success and failure. Your ideas and vision combined with my marketing and design expertise will be a sure success story.

https://www.edesigncreative.com
Next

Shining brighter because of you!